Diaceutics Announces Data to be Presented at 2024 ASCO Annual Meeting

​

Belfast and London, 28 May 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announced the acceptance of a poster and abstract for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held in Chicago 31 May through 4 June 2024.

The poster presentation, titled, "Effect of real time data-driven physician engagement on appropriate precision oncology testing", provides insight into precision medicine and addresses the gap between potential therapy eligibility and actual patient identification. By leveraging real-time data and personalized digital engagement with physicians, Diaceutics successfully increased biomarker testing rates and identified more patients eligible for precision therapies. This highlights the pivotal role of data-driven strategies in bridging clinical practice gaps and optimizing patient care pathways.

The online publication, titled, "NTRK positivity and conversion to appropriate personalized treatment is still a barrier", will highlight the challenges in accessing targeted treatments for rare cancer biomarkers like NTRK alterations. Despite the effectiveness of drugs like Entrectinib and Larotrectinib, the Diaceutics study shows that only a small percentage of patients with NTRK alterations receive related treatments. This indicates a need for improved strategies to ensure patients can benefit from personalized therapies, underscoring the importance of innovative approaches in diagnostics, healthcare delivery and stakeholder engagement.

Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, commented: "The data we will present at this year's ASCO further validates the critical link between data analysis and actionable insights. As we navigate through the landscape of clinical practice gaps, our mission remains clear, to drive innovation, foster collaboration, and ultimately ensure that every patient receives the tailored treatment they deserve. This commitment not only fuels our growth but also underscores our dedication to maximizing the economic viability of precision medicine, laying the groundwork for sustainable investment and transformative impact in healthcare."

This invitation to present the Company's research at one of the most influential meetings relating to pressing challenges within oncology, further solidifies Diaceutics' dedication to bridging clinical practice gaps, as they continue to lay the foundation for strategic investment opportunities that align with the evolving landscape of precision medicine.

Diaceutics will also be hosting an informal networking reception alongside KPMG and their combined Pharma customers which will provide an excellent opportunity for networking and discussion within the oncology community.

Details of the abstracts are as follows:

Information about the 2024 ASCO Annual Meeting may be accessed via the following website: https://conferences.asco.org/am/registration.

Enquiries: 

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

About ASCO

The ASCO Annual Meeting represents the world's largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss cutting-edge clinical research and therapeutics in oncology. This year, ASCO received and reviewed more than 7,000 abstracts for its Annual Meeting, ultimately selecting the final entries to be presented on a set of criteria including the strength and relevance of the research and whether it addresses an important and novel question.